Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-06-27 Purchase |
2024-07-01 08:00 am |
Taysha Gene Therapies Inc. | TSHA | Manning Paul B 10% Owner |
1,333,333 | $2.25 | $2,999,999 | 24,851,111 (Indirect Direct) |
View |
| 2023-11-17 Purchase |
2023-11-20 07:35 am |
Taysha Gene Therapies Inc. | TSHA | Manning Paul B 10% Owner |
100,000 | $1.63 | $163,000 | 23,517,778 (Indirect) |
View |
| 2023-08-24 Sale |
2023-08-25 4:30 pm |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer |
33,000 | $2.33 | $76,890 | 258,042 (Direct) |
View |
| 2023-08-16 Purchase |
2023-08-16 8:57 pm |
Taysha Gene Therapies Inc. | TSHA | Manning Paul B 10% Owner |
16,466,667 | $0.9 | $14,820,000 | 23,417,778 (Indirect) |
View |
| 2023-08-16 Purchase |
2023-08-16 8:53 pm |
Taysha Gene Therapies Inc. | TSHA | Stalfort John A III Director |
777,778 | $0.9 | $700,000 | 1,933,671 (Indirect Direct) |
View |
| 2023-08-16 Purchase |
2023-08-16 8:52 pm |
Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Chief Executive Officer |
444,444 | $0.9 | $400,000 | 1,536,715 (Indirect Direct) |
View |
| 2023-08-16 Purchase |
2023-08-16 8:51 pm |
Taysha Gene Therapies Inc. | TSHA | Donenberg Phillip B. Director |
111,111 | $0.9 | $100,000 | 114,111 (Direct) |
View |
| 2023-07-12 Sale |
2023-07-14 4:00 pm |
Taysha Gene Therapies Inc. | TSHA | Session R.A. II 10% Owner |
85,872 | $0.70769 | $60,771 | 9,153,927 (Indirect Direct) |
View |
| 2023-06-22 Sale |
2023-06-26 4:46 pm |
Taysha Gene Therapies Inc. | TSHA | Session R.A. II 10% Owner |
28,608 | $0.70327 | $20,119 | 9,239,799 (Indirect Direct) |
View |
| 2023-06-20 Sale |
2023-06-22 4:00 pm |
Taysha Gene Therapies Inc. | TSHA | Session R.A. II 10% Owner |
434,615 | $0.70831 | $307,844 | 9,268,407 (Indirect Direct) |
View |
| 2023-05-16 Purchase |
2023-05-18 4:44 pm |
Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar President and Head of R&D |
5,000 | $0.68 | $3,400 | 34,226 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-05-31 Option Award(A) |
2025-04-10 4:15 pm |
N/A 2033-02-02 |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran CHIEF FINANCIAL OFFICER |
12,462 | $0 | 12,462 (Direct) |
View |
| 2025-03-11 Tax Withholding |
2025-03-13 4:15 pm |
N/A N/A |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran CHIEF FINANCIAL OFFICER |
29,843 | $1.69 | 1,242,094 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-03 5:38 pm |
N/A 2035-01-02 |
Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Chief Executive Officer |
892,500 | $0 | 4,506,403 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-03 5:36 pm |
N/A 2035-01-02 |
Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar President and Head of R&D |
324,500 | $0 | 1,546,843 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-03 5:31 pm |
N/A 2035-01-02 |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran CHIEF FINANCIAL OFFICER |
431,000 | $0 | 1,702,937 (Direct) |
View |
| 2024-05-29 Option Award |
2024-05-31 4:18 pm |
N/A 2034-05-29 |
Taysha Gene Therapies Inc. | TSHA | Stalfort John A III Director |
147,660 | $0 | 2,081,331 (Direct) |
View |
| 2024-05-29 Option Award |
2024-05-31 4:18 pm |
N/A 2034-05-29 |
Taysha Gene Therapies Inc. | TSHA | Long Alison S Director |
147,660 | $0 | 147,660 (Direct) |
View |
| 2024-05-29 Option Award |
2024-05-31 4:18 pm |
N/A 2034-05-29 |
Taysha Gene Therapies Inc. | TSHA | Donenberg Phillip B. Director |
147,660 | $0 | 261,771 (Direct) |
View |
| 2024-05-29 Option Award |
2024-05-31 4:15 pm |
N/A 2034-05-29 |
Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director |
147,660 | $0 | 147,660 (Direct) |
View |
| 2024-02-02 Tax Withholding |
2024-02-06 4:42 pm |
N/A N/A |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran CHIEF FINANCIAL OFFICER |
1,288 | $1.51 | 840,937 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:43 pm |
N/A 2034-01-02 |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer |
590,413 | $0 | 1,432,638 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:42 pm |
N/A 2034-01-02 |
Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar President and Head of R&D |
863,617 | $0 | 1,761,460 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:41 pm |
N/A 2034-01-02 |
Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Chief Executive Officer |
1,184,688 | $0 | 3,906,091 (Direct) |
View |
| 2023-12-14 Option Award |
2023-12-18 4:50 pm |
N/A 2033-12-14 |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer |
187,582 | $0 | 187,582 (Direct) |
View |
| 2023-12-14 Option Award |
2023-12-18 4:47 pm |
N/A 2033-12-14 |
Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar President and Head of R&D |
334,005 | $0 | 334,005 (Direct) |
View |
| 2023-12-14 Option Award |
2023-12-18 4:46 pm |
N/A 2033-12-14 |
Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Chief Executive Officer |
466,550 | $0 | 466,550 (Direct) |
View |
| 2023-11-01 Option Award |
2023-11-03 4:41 pm |
N/A 2033-11-01 |
Taysha Gene Therapies Inc. | TSHA | Long Alison S Director |
43,800 | $0 | 43,800 (Direct) |
View |
| 2023-08-16 Gift |
2023-08-16 8:53 pm |
N/A N/A |
Taysha Gene Therapies Inc. | TSHA | Stalfort John A III Director |
50,000 | $0 | 1,933,671 (Direct) |
View |
| 2023-06-22 Option Award |
2023-06-26 4:50 pm |
N/A 2033-06-22 |
Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director |
36,200 | $0 | 36,200 (Direct) |
View |
| 2023-06-22 Option Award |
2023-06-26 4:50 pm |
N/A 2033-06-22 |
Taysha Gene Therapies Inc. | TSHA | Reape Kathleen Director |
36,200 | $0 | 36,200 (Direct) |
View |
| 2023-06-22 Option Award |
2023-06-26 4:49 pm |
N/A 2033-06-22 |
Taysha Gene Therapies Inc. | TSHA | Donenberg Phillip B. Director |
36,200 | $0 | 36,200 (Direct) |
View |
| 2023-06-22 Option Award |
2023-06-26 4:48 pm |
N/A 2033-06-22 |
Taysha Gene Therapies Inc. | TSHA | Stalfort John A III Director |
43,800 | $0 | 43,800 (Direct) |
View |
Ownership |
2023-06-26 4:46 pm |
N/A N/A |
Taysha Gene Therapies Inc. | TSHA | Stalfort John A III Director |
0 | $0 | 1,105,893 (Direct) |
View |
| 2023-05-31 Option Award |
2023-06-02 4:12 pm |
N/A N/A |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer |
6,230 | $0 | 291,042 (Direct) |
View |
| 2023-03-06 Other |
2023-03-08 7:38 pm |
N/A N/A |
Taysha Gene Therapies Inc. | TSHA | Session R.A. II 10% Owner |
251,296 | $0 | 9,954,318 (Direct) |
View |
| 2023-02-02 Option Award |
2023-02-06 9:12 pm |
N/A 2033-02-02 |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer |
205,975 | $0 | 472,096 (Direct) |
View |
| 2022-12-30 Option Award |
2023-01-04 4:51 pm |
N/A 2032-12-30 |
Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Chief Executive Officer |
1,106,131 | $0 | 1,106,131 (Direct) |
View |
| 2022-12-30 Option Award |
2023-01-04 4:51 pm |
N/A 2032-12-30 |
Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar President and Head of R&D |
790,093 | $0 | 790,093 (Direct) |
View |
| 2022-11-10 Option Award |
2022-12-23 4:15 pm |
N/A 2032-11-10 |
Taysha Gene Therapies Inc. | TSHA | Session R.A. II Director 10% Owner |
199,500 | $0 | 199,500 (Direct) |
View |